Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Rxo (RXO) EBITDA Margin (2021 - 2025)

Historic EBITDA Margin for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to 2.86%.

  • Rxo's EBITDA Margin fell 14200.0% to 2.86% in Q4 2025 from the same period last year, while for Dec 2025 it was 1.38%, marking a year-over-year decrease of 1500.0%. This contributed to the annual value of 1.38% for FY2025, which is 1500.0% down from last year.
  • Rxo's EBITDA Margin amounted to 2.86% in Q4 2025, which was down 14200.0% from 0.49% recorded in Q3 2025.
  • Rxo's 5-year EBITDA Margin high stood at 4.73% for Q2 2022, and its period low was 2.86% during Q4 2025.
  • In the last 5 years, Rxo's EBITDA Margin had a median value of 0.55% in 2023 and averaged 0.69%.
  • Per our database at Business Quant, Rxo's EBITDA Margin tumbled by -42300bps in 2022 and then surged by 15200bps in 2023.
  • Quarter analysis of 5 years shows Rxo's EBITDA Margin stood at 4.14% in 2021, then plummeted by -102bps to 0.09% in 2022, then skyrocketed by 1703bps to 1.43% in 2023, then crashed by -201bps to 1.44% in 2024, then tumbled by -99bps to 2.86% in 2025.
  • Its EBITDA Margin stands at 2.86% for Q4 2025, versus 0.49% for Q3 2025 and 2.09% for Q1 2025.